yingxue chen

Dr. yingxue chen

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 September 2019 in Journal of Materials Research and Technology
Verified
Journal Article
Open access
YCyingxue chen
yingxue chen
ZHZhiyuan Hong
Zhiyuan Hong
XZXiaoxin Zhang
Xiaoxin Zhang
MXMin Xia
Min Xia
QYQingzhi Yan
Qingzhi Yan
CGChangchun Ge
Changchun Ge

7 May 2021 in IEEE Transactions on Neural Networks and Learning Systems
Verified
Journal Article
Closed access
XLXinglan Liu
Xinglan Liu
BXBin Xu
Bin Xu
YSYingxin Shou
Yingxin Shou
QFQuan-Yong Fan
Quan-Yong Fan
YCyingxue chen
yingxue chen
This article concentrates on the event-based collaborative design for strict-feedback systems with uncertain nonlinearities. The controller is designed based on neural network (NN) weights adaptive law. The controller and NN weights adaptive law are only updated at the triggering instants determined by a novel composite triggering threshold. Considering the conservativeness of event condition, the state-model error is integrated into constructing the composite condition and NN weights adaptive law. In the context of the proposed mechanism, the requirements of system information and the allowable range of event-triggering error are relaxed. The number of triggering instants is greatly reduced without deteriorating the system performance. Moreover, the stability of the closed-loop is proved by the Lyapunov method following time-interval and sampling instants. Simulation results show the effectiveness of the scheme proposed in this article.

15 August 2020 in Cancer Research
Verified
Journal Article
Closed access
TYTimothy A. Yap
Timothy A. Yap
YCyingxue chen
yingxue chen
LBLisa H. Butler
Lisa H. Butler
SLSi-Houy Lao-Sirieix
Si-Houy Lao-Sirieix
ECElaine Cadogan
Elaine Cadogan
EDEmma Dean
Emma Dean
Background: DNA-dependent protein kinase (DNA-PK) is a critical sensor of DNA double-strand breaks (DSBs) and orchestrates their repair through non-homologous end joining (NHEJ). AZD7648 is a novel, potent and highly selective inhibitor of DNA-PK being evaluated as monotherapy or in combination with doxorubicin or olaparib in a Phase I/II first-in-human study. The objectives of this trial are to assess safety and tolerability, establish a Recommended Phase 2 Dose (RP2D) and evaluate early clinical activity. Pre-clinically, AZD7648 monotherapy leads to tumour growth inhibition in ATM deficient models in vivo, demonstrating potential to enhance the effects of endogenous tumour damage clinically. AZD7648 is also an efficient sensitizer of doxorubicin-induced DNA damage and demonstrates enhanced efficacy in combination with olaparib. Both combinations induce sustained regressions in vivo across a range of tumour xenografts with differing genetic alterations, accompanied by robust pharmacodynamic biomarker modulation. These data provide the rationale to explore AZD7648 as monotherapy and in combination with either doxorubicin or olaparib. Methods: This is a Phase I/IIa study comprising 3 modules: Core Module (AZD7648 monotherapy - dose escalation), combination module 1 (AZD7648 + pegylated liposomal doxorubicin [PLD]), and combination module 2 (AZD7648 + olaparib). Each combination evaluates AZD7648 in a Phase I escalation (Part A) and a Phase IIa expansion (Part B). Patients are assigned to a single study Part, but intra-patient dose escalation is permitted in Part A. The study incorporates a Bayesian adaptive dose escalation trial design which combines prior expectations about the dose toxicity relationship and applies the data at the end of each cohort to recommend a dose for the next cohort. The study will investigate pharmacodynamic (PD) and exploratory biomarker (DNA, RNA, proteins or metabolites) profiles in exclusive cohorts, and study their relationship to drug effect. Eligible patients are aged ≥18 years with advanced solid tumours, who have failed standard therapies. In Part A, patients are assessed for dose-limiting toxicities during the evaluable period. Blood samples are collected for pharmacokinetic (PK) analysis following a single dose of AZD7648 and at steady state. Single patient cohorts may occur for the first four cohorts (or until drug-related ≥ Grade 2 toxicity). From cohort 5 onwards, a minimum of 3 patients will be enrolled into each dose cohort until the Maximum Tolerated Dose, Maximum Feasible Dose or RP2D is identified. Enrolment into the study commenced in Oct 2019 and is currently enrolling cohort 3 in the monotherapy dose escalation. To date, no DLTs have been reported in prior cohorts. [clinicaltrials.gov identifier: NCT03907969] Citation Format: Timothy A. Yap, Yingxue Chen, Lisa H. Butler, Si-houy Lao-Sirieix, Elaine Cadogan, Lenka Oplustil O'Connor, Karthick Vishwanathan, Younghwa Kim, Dónal Landers, Emma Dean. AZD7648: A Phase I/IIa first-in-human trial of a novel, potent and selective DNA-PK inhibitor in patients with advanced malignancies [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr CT248.

19 September 2022 in Wind Engineering
Verified
Journal Article
Open access
YCyingxue chen
yingxue chen
MSMohammad Hasan Shaheed
Mohammad Hasan Shaheed
Ranjan VepaRanjan Vepa
Ranjan Vepa
A common strategy in controlling a permanent magnet synchronous generator (PMSG) driven by a wind turbine is the maximization of output power of the wind turbine itself. A control strategy must be adopted, is to deliver a desired reduced amount of power whenever it is required. In order to realize the direct control of wind turbine output power across a wide range of wind speeds, a linearized parameter varying dynamic model of the nonlinear wind turbine system including wind disturbances is developed and used in this paper. The stability of the wind turbine system is analyzed and a blade pitch controller is designed, based on the linearized, parameter-varying, model-predictive control and is validated. Thus, the wind turbine is regulated in a way that the generator delivers the demanded power output to the load. Moreover, the blade pitch control system also performs the key function of augmenting the stability of the wind turbine, for the right choice of the gains.

10 September 2024 in IET Renewable Power Generation
Verified
Journal Article
Open access
MXMeng Xian‐Long
Meng Xian‐Long
ZPZhang Pu
Zhang Pu
HYHou Yi‐Chao
Hou Yi‐Chao
LBLiu Bei
Liu Bei
YCyingxue chen
yingxue chen
TMTapas K. Mallick
Tapas K. Mallick
Laser wireless energy transmission is a widely utilized method, yet its efficiency is constrained by a variety of factors. In order to improve the conversion efficiency of the receivers of the laser wireless power transmission (LWPT) system, the square elliptic hyperboloid (SEH) concentrating module designed for LWPT system receivers is developed. By analysing the I–V characteristic curves from the results of the experiments and employing non‐linear parameter regression, a corrected battery characteristic curve was derived within a specific laser irradiation range. On this basis, an optical–thermal–electric multi‐field coupling characteristic model was developed. The finite element method is used to simulate the multi‐field coupling characteristics and conversion efficiency of the receiving end under diverse working conditions (including different rotation angles and different divergence angles) of the concentrating photovoltaic module. Research shows: First, the larger the divergence half‐angle β of the laser beam, the more obvious the improvement of the effective optical efficiency of the system by the SEH concentrator. Second, the short‐circuit current and the maximum output power of the PV cell at the receiving end are significantly improved by the SEH concentrator, and the improvement effect is more obvious with the increase of the divergence angle and the rotation angle. Third, SEH concentrators did not significantly affect the fill factor of PV cells.